Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $722,700.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin Mcculloch sold 90,000 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $8.03, for a total transaction of $722,700.00. Following the sale, the insider directly owned 1,691,126 shares in the company, valued at $13,579,741.78. This represents a 5.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Stock Up 3.5%

Shares of NASDAQ XERS traded up $0.28 during midday trading on Thursday, hitting $8.28. The company’s stock had a trading volume of 3,702,785 shares, compared to its average volume of 1,901,927. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of 138.00 and a beta of 0.62. The business’s fifty day simple moving average is $6.51 and its two-hundred day simple moving average is $6.61. Xeris Biopharma Holdings, Inc. has a 1 year low of $4.62 and a 1 year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The company had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. On average, equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Analysts Set New Price Targets

XERS has been the subject of several analyst reports. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Xeris Biopharma has a consensus rating of “Hold” and an average target price of $10.80.

Hedge Funds Weigh In On Xeris Biopharma

Hedge funds have recently made changes to their positions in the company. Kestra Advisory Services LLC purchased a new stake in shares of Xeris Biopharma in the 4th quarter valued at about $25,000. KBC Group NV purchased a new position in Xeris Biopharma during the 1st quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd grew its stake in Xeris Biopharma by 9,276.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after buying an additional 7,421 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after acquiring an additional 1,820 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Xeris Biopharma by 179.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after purchasing an additional 5,000 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.